We have characterised the transdifferentiation of human HepG2 (hepatoma) cells to pancreatic cells following introduction of an activated version of the pancreatic transcription factor Pdx1 (XlHbox8-VP16). The following questions are addressed: (1) are all types of pancreatic cells produced? (2) is the requirement for expression of the transgene temporary or permanent? (3) are the transdifferentiated b-cells responsive to physiological stimuli? The results showed that both pancreatic exocrine cells (by detection of amylase protein), and endocrine cells (by detecting insulin, glucagon and somatostatin proteins) are induced after XlHbox8VP16 transfection. Moreover, the hepatic phenotype becomes suppressed during transdifferentiation of hepatocytes to pancreatic cells. Requirement for the transgene is only temporary and it is no longer required once the pancreatic differentiation program is activated. Finally, we provided results to suggest that the transdifferentiated cells are functional by detecting: (1) functional markers for pancreatic b-cells including prohormone convertase 1/3 (PC1/3), insulin C-peptide and glucagon-like peptide 1 receptor (GLP-1R), (2) increased insulin mRNA expression after treatment of cells with GLP-1 and betacellulin, physiological stimuli that regulate pancreatic function and (3) elevated insulin secretion after glucose challenge. The transdifferentiation of hepatic to pancreatic cells represents one possible source of b-cells for human islet transplantation and this study shows that such a transdifferentiation can be achieved in vitro. q
Introduction
Transdifferentiation is defined as the conversion of one differentiated cell type to another. Transdifferentiation belongs to a class of cell-type conversions known as metaplasias that includes also conversion of tissue-specific stem cells (Slack, 1986; Tosh and Slack, 2002) . The phenomenon of transdifferentiation is important to study because it will help to deepen our understanding of the developmental biology of the tissues that interconvert. Also, if we can clarify the molecular basis of the switch in phenotype, it might be possible to bring about the production of specific cell types that can be used for the therapeutic treatment of degenerative disorders such as Parkinson's disease and diabetes mellitus.
Tissues that undergo transdifferentiation generally arise from adjacent regions in the developing embryo (Slack and Tosh, 2001) . In normal development, the expression of one or more transcription factors encoded by 'master-switch' genes is responsible for distinguishing the adjacent tissue types. Transdifferentiation occurs because of the ectopic expression of the master-switch gene, or its inactivation, at a later stage.
One well-characterised example of transdifferentiation is that between liver and pancreas. During early development, the liver and ventral pancreas originate from the adjacent regions of the anterior endoderm close to the cardiac mesoderm and surrounded by the mesenchyme of the septum transversum (Jung et al., 1999; Rossi et al., 2001 ). The two tissue types are thought to arise depending on the level of fibroblast growth factor secreted by the mesenchyme (Deutsch et al., 2001) . It is possible to interconvert liver Mechanisms of Development 122 (2005) and pancreas under certain pathological conditions. For example, hepatocytes can be induced in the pancreas of rats following a copper-depletion-repletion regime (Rao et al., 1986a) , and in transgenic mice overexpressing KGF (FGF7) in pancreatic islets (Krakowski et al., 1999) . More recently, it has been shown that it is possible to convert pancreatic cells to hepatocytes in vitro by culture with the synthetic glucocorticoid dexamethasone (Shen et al., 2000) . On the other hand, for the reverse transformation, ectopic pancreatic exocrine cells have been detected in the livers of rats treated with polychlorinated biphenyls (PCBs) (Rao et al., 1986b) . Over recent years, much effort has focused on identifying transcription factors that are important for pancreas development. Among these are likely to be found the master switch gene that distinguishes pancreas and liver. One of the potential factors is the gene encoding the homeodomain transcription factor pancreatic-duodenal homeobox 1 (pdx-1, also known as insulin-promoting factor-1, ipf-1). The absence of the pancreas in pdx-1 knockout mice (Jonsson et al., 1994) and the pancreatic agenesis in human patients exhibiting homozygous loss of function of the pdx-1 gene (Stoffers et al., 1997) have shown that pdx-1 plays an essential role in pancreas development.
Ferber et al. introduced rat pdx-1 into mice using adenovirus and detected the expression of amylase (exocrine), insulin (endocrine), prohormone convertase 1/3 (PC1/3, a functional marker for insulin maturation), and mouse pdx-1 itself (self-regulatory feedback) in the livers of infected mice (Ferber et al., 2000; Ber et al., 2003) . In addition, Zalzman et al. have obtained insulin-producing cells by transferring pdx-1 into human foetal liver progenitor cells (Zalzman et al., 2003) . These studies showed activation of pancreatic genes in liver cells but they did not demonstrate complete transdifferentiation.
In an earlier publication, we described the appearance of ectopic pancreas in transgenic tadpoles of Xenopus laevis. We also showed expression of amylase and insulin proteins in cultured human hepatoma HepG2 cells (Horb et al., 2003) . Both models were based on introducing the Xenopus homologue of pdx-1 (known as XlHbox8), fused to a sequence encoding the transcriptional activating domain VP16, and driven by a liver-specific transthyretin promoter. The present work expands the HepG2 cell analysis to determine in more detail the molecular basis of the conversion of liver to pancreas and to characterise the cell types formed.
The results show that: (1) several different pancreatic cell types are formed, and hepatic markers are down-regulated, in the transdifferentiated cells; (2) expression of the transgene XlHbox8VP16 becomes downregulated and its hepatic-specific promoter is inactivated during the conversion of liver to pancreas. (3) the transdifferentiated insulinproducing cells show various functional properties of real beta cells. In particular they show elevation of insulin synthesis in response to glucagon-like peptide 1 and betacellulin, and they show enhanced secretion of insulin in response to high external glucose.
Results

Formation of multiple pancreatic cell types
HepG2 cells are a well-characterised hepatoma cell line that shows the expression of some hepatic differentiated markers, such as the carrier proteins albumin, transthyretin and transferrin, acute phase protein haptoglobin and the protease inhibitor a-1 antitrypsin. Because of their differentiated properties, they are considered as a suitable model for investigating the phenomenon of liver to pancreas transdifferentiation.
The pancreas is composed of multiple cell types, including exocrine and endocrine cells (Fig. 1A-C) . Therefore, the first question we addressed was whether expression of the TTR-XlHbox8VP16 plasmid simply induces pancreatic gene expression, or whether it is possible to induce the formation of specific pancreatic cell types. We demonstrated that pancreatic exocrine amylase-positive cells (Fig. 1D ) and endocrine cells including insulin- (Fig. 1E ), glucagon- (Fig. 1F) , and somatostatin-expressing (Fig. 1G ) cells were induced by the fifth day after TTR-XlHbox8VP16 transfection. The only principal pancreatic cell type not observed was pancreatic polypeptide-expressing PP cells (Fig. 1H ). This observation may be explained because of the small proportion of PP cells in the normal pancreatic islets (Slack, 1995) . By comparison, the HepG2 cells that were transfected with the control construct TTR-VP16 (i.e. lacking the functional Xlhbox8 sequence) showed no pancreatic cell types visible by immunostaining (data not shown).
An important issue is the fidelity of differentiation of the pancreatic cell types. In normal postnatal endocrine cells only one of the hormones is expressed. To investigate this, we co-stained transdifferentiated HepG2 cells for pairs of two different pancreatic markers. The results showed that no pancreatic proteins, including amylase, insulin or glucagon, were co-expressed in the same transdifferentiated cells (Fig. 1I ). So they appear to be normal differentiated pancreatic cell types rather than liver cells that are expressing some pancreatic genes.
In order to examine the time course of events, the expression of the pancreatic products was studied by RT-PCR. This approach is complementary to the immunodetection because it can show low levels of the messages and can give quantitative results using the Light Cycler. Qualitative RT-PCR results showed that there is low-level expression of some, but not all, pancreatic genes, in the untreated HepG2 cells. This includes amylase and somatostatin, and a quite appreciable expression of pancreatic polypeptide ( Fig. 2A) . This PP expression is not detected by immunostaining which suggests that it is low level but present in the entire cell population. The expression of these pancreatic products in untreated HepG2 cells indicates that although they have many properties of normal hepatocytes, they are not entirely normal. The real-time quantitative RT-PCR of cells transfected with TTR-XlHbox8VP16 shows that expression of amylase and insulin, increase sharply with the main rise occurring between 3 and 5 days after transfection (Fig. 2B,C) , consistent with the timing of appearance of the cells immunoreactive for these pancreatic proteins. Furthermore there is a low but reproducibly detectable signal from endogenous human pdx1 in the transfected cells (Fig. 2D) , showing that a consequence of the action of XlHbox8-VP16 is to activate its own gene in the HepG2 cells.
Hepatic proteins in the transdifferentiated cells
To examine the fate of the hepatic proteins in the cells expressing pancreatic proteins, we performed dual-immunostaining for three hepatic proteins: albumin, transferrin and a-1 anti-trypsin, along with the b-cell marker, insulin. The results indicated that by 5 days the hepatic proteins in transdifferentiated cells had been lost from some insulinpositive cells cells but were still present in others ( Fig. 3D-I ). By contrast, the cells transfected with the control DNA construct TTR-VP16 showed no insulin expression or loss of hepatic protein expression (Fig. 3A-C) . Fig. 3J shows the proportions of cells without or with hepatic marker expression and Fig. 3K shows the time course of albumin expression in transfected cells, identified by immunostaining for the VP16 protein epitope. These results show that by 5 days some cells have completely lost hepatic proteins and so are presumably fully transdifferentiated. Furthermore, there is a progressive loss of albumin over this period, so although the majority of cells do still contain liver proteins at 5 days it is likely that expression has been turned off and the protein is gradually decaying. Because the transdifferentiated cells represent a small proportion of the total, there is no decline of liver products when measured by bulk biochemical methods. With this system it is not normally possible to continue observations beyond 5 days because the cells reach confluence at this time and the transfected cells are lost on subculturing.
XlHbox8VP16 is only transiently required during conversion of liver to pancreas
We then explored in more detail the time-course of what happens following XlHbox8VP16 transfection. The strategy was based on using the plasmid TTR-XlHbox8VP16; elastase-GFP and detecting the number of VP16-or GFPexpressing cells in the culture. In principle, we should expect the XlHbox8VP16 to be expressed initially because it is driven by the TTR promoter which will be active in HepG2 cells. But once the cell has acquired a pancreatic identity we expect the TTR promoter to be shut down and the pancreas-specific elastase promoter to be activated. We determined the expression of VP16 (which is controlled by the TTR promoter) and GFP (which is controlled by the elastase promoter) by immunofluorescence. The results showed that at various time points (from the 1st day to the 5th day after transfection of the TTR-XlHbox8VP16; elastase-GFP plasmid), the VP16 expression gradually decreased while the GFP increased (Fig. 4A ). The cells displaying expression of only one of the two products show a crossover in frequency between 2 and 3 days after transfection. At all times, the majority of cells displayed both markers but this is not surprising because the XlHbox8VP16 protein may be expected to persist for some time after its promoter is shut down. The qualitative and real-time RT-PCR results for XlHbox8 both shows a drop from 1 to 3-5 days consistent with an early shut down of the TTR promoter (Fig. 4B,C) .
To further confirm the repression of the hepatic promoter in transdifferentiated cells, we compared promoter activity in the cells transfected with TTR-XlHbox8VP16 and those transfected with CMV-XlHbox8VP16. The CMV promoter is expected to remain active regardless of the state of differentiation of the cell. Here, the proportion of VP16-positive cells was measured on each day, and Fig. 4D shows the ratio of proportions for the TTR-versus the CMVconstruct. There is a progressive decrease in this ratio, consistent with a preferential shut-down of the TTR promoter in the transfected cells. This figure does not match Fig. 4A quantitatively, but the precision of the results is limited by the fact that there is a certain loss of transfected cells during the culture period, and this means that the results should be treated as qualitative rather than quantitative.
VP16 does not work by promoting nuclear localisation
Our previous work has shown that the VP16 domain is essential to achieve complete transdifferentiation (Horb et al., 2003) . We have considered that part of the activity of the VP16 domain may depend on increasing nuclear localisation of the Pdx1 protein ( Fig. 5A ; Triezenberg et al., 1988; Macfarlane et al., 1999) . To investigate this possibility, we generated two more pcDNA3 plasmids: CMV driving mouse pdx1 and CMV driving mouse pdx1VP16. Then we transfected these two constructs into HepG2 cells and into a human pancreatic ductal cell line Panc-1 (which does not express Pdx1) to investigate the intracellular localisation of Pdx1. These experiments were done with the mouse rather than the Xenopus protein because of the availability of a suitable antibody to detect it.
As shown in Fig. 5B -E, Pdx-1 is expressed in both the nucleus and the cytoplasm in both HepG2 and Panc-1 cells. There was no significant difference in nuclear localisation between Pdx-1 and Pdx1VP16 in either cell line. The proportion of nuclear Pdx-1 or Pdx1VP16 in both cell lines was estimated at 65-75% of total transfected cells ( Fig. 5F,G) . We conclude therefore that VP16 does not exert its effect by increasing nuclear localisation.
Transdifferentiated b cells respond to physiological stimuli
While the immunostaining results suggest the production of differentiated pancreatic cell types, the question arises whether these cells are functional. To address this problem, we performed a number of assays for measuring b-cell function. First of all, we determined, if part of the insulin biosynthesis machinery was present in transdifferentiated cells. Prohormone convertase (PC1/3) is involved in the formation of insulin from insulin precursor proteins preproinsulin and proinsulin (Goodge and Hutton, 2000) . As shown in Fig. 6A , we found that PC1/3 expression was induced at the 3rd day following transfection and increased thereafter. We also investigated the co-localisation of insulin and C-peptide, the products generated after the PC1/3-catalysed processing step. The co-expression of these two proteins in the same cells after XlHbox8VP16 transfection (Fig. 6B,C) , confirms the presence of the insulin Betacellulin is a member of the epidermal growth factor (EGF) family and was first purified from tissue of a human insulinoma (Shing et al., 1993) . It plays a role in regulating pancreas regeneration (Li et al., 2003; Yamamoto et al., 2000) and can convert pancreatic exocrine-derived AR42J cells into insulin-producing cells (Mashima et al., 1996) . These observations indicate that pancreatic b-cells are responsive to betacellulin. We examined the insulin mRNA expression following treatment with or without 10 ng/ml betacellulin at various time points (12-, 36-and 60-h) in XlHbox8VP16 transfected HepG2 cells. After treatment with betacellulin for 60 h, there was a 100-fold increase in expression of insulin mRNA compared to calibrators (Fig. 6E) .
We also determined the effect of glucagon-like peptide 1 (GLP1) on transdifferentiated cells. GLP1 is a peptide secreted by intestinal L-cells via the posttranslational modification of the proglucagon gene Drucker, 2001; Perfetti and Merkel, 2000) and has been reported to regulate pancreatic proliferation (Edvell and Lindstrom, 1999) and insulin secretion (Drucker, 2001; Wang et al., 1995) . Five days after transfection with XlHbox8VP16 the GLP1 receptor mRNA (GLP1R) is upregulated by about 5.5-fold (Fig. 6D) . The formation of insulin mRNA is stimulated by GLP1 in the transdifferentiated cells, although not by as much as in betacellulin treated cells (Fig. 6E) .
In terms of beta cell function, the most important and characteristic property is the ability to secrete insulin in response to an elevation of external glucose concentration (Rajagopal et al., 2003) . Because of the low proportion of insulin-positive cells as a fraction of the total cells in the transfected HepG2 cell system, the expected effect is small. However we have successfully measured the insulin concentration in the medium of 5 day XlHbox8VP16-transfected cells after challenge with 25 mM glucose, using a sensitive ELISA kit (Fig. 6F ). This shows that there is a reproducible and significant increase of insulin secretion. No increase is seen for transfected cells not exposed to high glucose, nor for control (TTR-VP16) transfectants, either exposed or not exposed to high glucose.
Discussion
The ability to convert one cell type to another has enormous therapeutic potential for the treatment and cure of degenerative disorders (Ball et 2004). For example, the conversion of a readily available cell type to pancreatic b-cells may make it possible to carry out many more pancreatic islet grafts on patients with severe diabetes (Hussain and Theise, 2004; Nakajima-Nagata et al., 2004; Ramiya et al., 2000; Serup et al., 2001) .
In previous experiments, Ferber et al. (2000) utilised a first-generation adenoviral vector containing pdx1 to infect streptozotocin (STZ)-induced diabetic mice. The results showed that pancreatic genes were induced and the levels of blood glucose were returned to normal levels (Ferber et al., 2000; Ber et al., 2003) . Koizumi et al. also demonstrated the induction of insulin-producing cells in STZ-treated mice after infection with pdx-1 in a replication-deficient recombinant adenoviral vector (Koizumi et al., 2004) . Miyatsuka et al. revealed that pancreatic endocrine and exocrine products as well as some functional markers (e.g. islet-type glucokinase and the sulfonylurea receptor) were detected in the liver where pdx-1 was ectopically expressed in a transgenic mouse model (Miyatsuka et al., 2003) . These studies all showed the activation of pancreatic genes in liver cells, but they did not show the formation of differentiated pancreatic cell types. In our own experiments with Xenopus, we found that the unmodified Pdx1 or XlHbox8 were not active in bringing about transdifferentiation of liver to pancreas. But inclusion of the VP16 domain made both the mouse and Xenopus proteins active (Horb et al., 2003) . The ectopic pancreas in our Xenopus tadpoles was clearly differentiated, but there are questions about the degree of maturity of the liver at the time of transgene expression. So we felt it advisable to investigate the degree of pancreatic differentiation in the HepG2 cell system.
In the present work our results show that XlHbox8VP16 is indeed able to induce different pancreatic cell types, including exocrine cells and a range of endocrine cells (at least alpha, beta and delta types) following transfection. Additionally, we have shown that XlHbox8VP16 can repress the hepatic phenotype. It is true that the proportion of transfected cells that become differentiated pancreatic cells is quite small, and this suggests that the HepG2 cells may have some intrinsic variability of competence whose basis we do not currently understand.
We demonstrated that transgene expression (as determined by the detection of VP16 or XlHbox8) is only transiently required for transdifferentiation of hepatocytes to pancreatic cells, as by the end of the culture period a proportion of pancreatic cells have lost transgene expression. This effect was also found in adenoviral Ad-CMV-rPdx1 infected mice (Ber et al., 2003) . From a clinical point of view, transient action would be beneficial because it would remove the need for transgene integration which might have problems associated with insertional mutagenesis.
We do not know for sure why the VP16 domain changes the biological activity of Pdx-1 so profoundly. In this work, it is shown that there is no significant effect on the degree of nuclear localisation. One factor is probably the fact that VP16 is a very active transcriptional activation domain. Another is that it may be able to act in isolation in the absence of the various partner proteins that are used by Pdx-1 in the context of the normal pancreatic cell types (Andersen et al., 1999; Glick et al., 2000; Goudet et al., 1999; Liu et al., 2001) .
Our results are a further example showing that it is possible to alter the cellular phenotype by introducing a single 'master-switch gene' into cells. Comparable recent findings include the conversion of bile ductal epithelium to pancreatic tissues in Hes-1 knockout mice. Hes1 is a basic helix-loop-helix transcription factor that is a negative regulator in Delta-Notch pathway which is considered important in endocrine development (Sumazaki et al., 2004; Burke et al., 2004) . In addition, the transition from duodenal epithelium to pancreatic progenitors by inactivation of pancreatic transcription factor 1a (Ptf1a) was also shown recently (Kawaguchi et al., 2002) .
Building on the previous results from our group (Horb et al., 2003) , the present work confirms the existence of transdifferentiation to pancreatic cell types, shows that the cells are functional, and indicates that the transgene need not remain active in the long term. There are three main questions that still need to be addressed. First, can XlHbox8VP16 induce conversion of non-pancreatic cells to beta-cells including cells from other germ layers (e.g. mesoderm or ectoderm)? Secondly, are other pancreatic transcription factors active? Thirdly, is it possible to get a higher yield of beta-cells by combining different transcription factors with XlHbox8VP16? These will all be the subjects of future work.
Experimental procedure
Chemicals
Glucagon-like peptide 1 (GLP-1, fragment 7-37) and human recombinant betacellulin were purchased from Sigma, UK.
Cells and in vitro pancreatic buds culture
The human hepatoma cell line HepG2 was obtained from the European Collection of Cell Cultures (ECACC, UK) and maintained in Dulbecco's Modified Eagle's Medium (Sigma, UK) containing 100 units/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, 1!MEM Non-Essential Amino Acids (all were from Sigma, UK) and 10% Foetal Bovine Serum (Gibcoe/Invitrogen Life Technologies). The RIN-5F insulinoma cell line was purchased from ECACC and kept in RPMI1640 medium (Sigma, UK) containing 100 units/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, and 10% Foetal Bovine Serum. The human pancreatic ductal cell PANC-1 (also obtained from the ECACC), was cultured in Dulbecco's Modified Eagle's Medium containing 100 units/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, and 10% Foetal Bovine Serum.
E11.5 dorsal pancreatic buds were obtained from MF1 albino mice bred at the University of Bath. Adult mice were killed by cervical dislocation and the decidua removed and placed into ice-cold PBS. The embryos were dissected out and placed in Minimal Essential Medium (MEM) containing Hank's salts (Sigma, UK). The embryos were opened laterally and the stomach located. The dorsal pancreas was identified at the posterior end of the stomach and the tissue was removed with fine forceps and needles. Isolated pancreatic buds were placed cut surface down into stainless steel cloning rings on fibronectin-coated coverslips. These were in 35 mm culture dishes containing 2 ml of Basal Essential Medium (BEM) with Earle's salts (Sigma, UK) containing 2 mM L-glutamine, 50 mg/ml gentamycin (Gibcoe/Invitrogen Life Technologies) and 20% Foetal Bovine Serum. After 24 h of culture, the cloning ring was removed and was replaced with fresh medium. Medium was changed every 2 days until day 5-7. The coverslips (22!22 mm 2 , SLS Ltd) were prepared by rinsing with 2% 3-aminopropyltriethoxysilane (APTS, Sigma) in acetone overnight, followed by washing twice in acetone and the sterile water. The coverslips were then dried at 37 8C and heat sterilised at 180 8C for at least 3 h. Forty microlitres of 50 mg/ml bovine fibronectin (Gibcoe) was applied to the centre and allowed to dry.
Plasmid construction
We used the plasmid pCS2-TTR-XlHbox8VP16; elastase-GFP constructed by Horb (Horb et al., 2003) . In this construct the XlHbox8 gene is controlled by the transthyretin (TTR) promoter, and the green fluorescent protein (GFP) reporter is controlled by the elastase promoter. The plasmid was modified by removing the elastase-GFP portion with NotI and religating with T4 ligase (New England Biolabs), and referred to as pCS2-TTRXlHbox8VP16. The control pCS2-TTR-VP16 construct was produced by cutting pCS2-TTR-XlHbox8VP16 with ClaI to remove the XlHbox8 portion. A pcDNA3 plasmid containing the mouse Pdx1 sequence instead of the Xenopus XlHbox8, with or without the VP16 sequence was constructed as described by Horb et al. (2003) .
Antisera and dilution factors
The source and working dilution factors of the antibodies are as follows: Primary antibodies-rabbit polyclonal antiamylase antibody (1:300), rabbit polyclonal anti-albumin antibody (1:500), rabbit polyclonal anti-a 1 -antitrypsin antibody (1:100), mouse monoclonal anti-green fluorescence protein (GFP) antibody (1:300), mouse monoclonal anti-glucagon antibody (1:100), guinea pig anti-insulin whole antiserum (1:300), mouse monoclonal anti-VP16 antibody (1:100) and rabbit polyclonal anti-VP16 antibody (1:250) were from Sigma; rabbit polyclonal anti-somatostatin antibody (1:100) and rabbit polyclonal anti-transferrin antiserum (1:200) were from DAKO (Ely, Cambridge), rabbit polyclonal anti-pancreatic polypeptide antibody (1:100) was obtained from Zymed Laboratories. Rabbit polyclonal anti-human C-peptide antibody (1:100) was obtained from Acris Antibodies. Rabbit polyclonal antimouse IPF1 (insulin promoter factor 1)/PDX1 (pancreatic duodenal homeobox 1) antibody (1:100) was made by J.M.W. Slack against an 18 amino acid C-terminal peptide conjugated to keyhole limpet haemocyanin. Secondary antibodies-Aminomethylcoumarin acetate (AMCA)-conjugated horse polyclonal anti-mouse antibody was from Vector Laboratories (Burlingame, CA). Fluorescein 5 0 -isothiocyanate (FITC)-conjugated goat polyclonal antirabbit antibody, FITC-conjugated horse polyclonal antimouse antibody, FITC-conjugated goat polyclonal anti-guinea pig IgG antibody were from Vector Laboratories (Burlingame, CA), Texas Red-conjugated horse polyclonal anti-mouse antibody was from Vector Laboratories (Burlingame, CA), Tetramethyl rhodamine isothiocyanate (TRITC)-conjugated swine polyclonal anti-rabbit IgG antibody was from DAKO (Ely, Cambridge). Secondary antibodies were diluted at 1/200. All of the antibodies were freshly made in 2% blocking buffer (Roche Diagnostics Molecular Biochemicals) before use.
Immunofluoresence staining
For immunofluorescence staining, transfected cells were rinsed with PBS to remove any excess medium and then fixed with 4% Paraformaldehyde (PFA, BDH) for 20-30 min, the cells were permeabilised with 0.1% (vol/vol) Triton X-100 in PBS for 30 min. In contrast to cells, embryonic pancreatic buds were fixed in MEMFA. MEMFA was prepared by mixing the following reagents: 10% formaldehyde, 0.1 M MOPS (pH 7.4) (Sigma), 2 mM ethylene-glycotetraacetic acid (EGTA, Sigma) and 1 mM MgSO 4 (Sigma). Tissues was permeabilised with 1% Triton X-100 in PBS for 30 min. Afterwards, cells or tissues were incubated in 2% blocking buffer (Boehringer Mannheim) for at least 1 h. The coverslips were then incubated with primary antibody overnight at 4 8C. On the following day, the coverslips were washed with PBS. The fluorescentlyconjugated secondary antibodies were added to the coverslips for 3 h then washed with PBS. The slides were mounted with gelvatol mounting medium. Gelvatol is prepared by dissolving 20 g of polyvinyl alcohol (Aldrich) in 80 ml of 10 mM Tris, pH 8.6, including 0.2% NaN 3 (BDH) , then mixed with 50 ml glycerol containing 3 g of n-propyl gallate (Sigma). If there is more than one antigen to be detected with various colours, the other primary and secondary antibodies were added sequentially with the same protocol described above.
For cell counting experiments, cells were incubated with antibodies followed by 4,6-diamidino-2-phenylindole (DAPI, Sigma) staining. DAPI was dissolved in PBS at 500 mg/ml and used at 1:1000 dilution. Coverslips were incubated in DAPI for 15-20 min in room temperature before counting in gelvatol mounting medium.
Transfection of plasmids
Transfection of plasmids into HepG2 cells was performed with GeneJuice (Novagen) transfection reagent according to the manufacturer's instructions. The medium was replaced with fresh medium after 24 h of transfection. The cells were cultured for a further 5 days, then analysed by immunofluorescence staining or reverse transcriptase polymerase chain reaction (RT-PCR). The transfection efficiency was 2-3% and the proportion of transfected cells expressing insulin by immunofluorescence was about 1%: corresponding to about 50 positive cells per coverslip. 
Primers for polymerase chain reactions
Qualitative RT-PCR
Total RNA was extracted from transfected and control HepG2 cells using the TRI reagent (Sigma, Poole, UK). Digestion with RQ1 RNase-free DNase (Promega, Southampton, UK) was performed to eliminate any contaminating genomic DNA. The concentration of extracted RNA was measured on a Beckman Spectrophotometer. The ratio of 260-280 nm of each sample ranged from 1.8 to 2.0. Messenger RNA was isolated from total RNA by using SuperScripte First-Strand Synthesis System for RT-PCR (Invitrogen Life Technologies). Messenger RNA (mRNA) was first isolated by incubation of Oligo(dT) 12-18 oligonucleotides from 8 mg extracted total RNA; complementary DNA (cDNA) was prepared by SuperScripteII reverse transcriptase treatment. cDNA samples were incubated with 2 units RNase H at 37 8C for 20 min to remove the RNA-cDNA hybridised residues. Polymerase chain reactions containing the mixture of the same concentration of cDNA, 1! PCR buffer, 1.5 mM MgSO 4 , 0.2 mM dNTP, 50 ng sense/antisense primers and 1.25 U Platinum Taq polymerase (Invitrogen Life Technologies) were processed in a DNA thermal cycler using the following conditions: denatured at 94 8C for 1 min, amplification at 58 8C for 1 min and elongation at 72 8C for 1 min for 30-40 cycles. The samples were analysed in 1.5% agarose electrophoresis with 1 kb ladder marker (Invitrogen Life Technologies).
Lightcycler quantitative real-time PCR
To obtain more quantitative results for the different samples at different time points after transfection, we performed Real-Time PCR using the Lightcycler system (Roche Diagnostics). The calibrators used in the human insulin and glucagon PCR reaction were composed of mixed cDNA from 10% human pancreatic cells (kindly supplied by Dr R.M. Smith, Southmead Hospital, Bristol, UK) and 90% HepG2 cells. The calibrator used for the amylase, somatostatin and pancreatic polypeptide was cDNA from TTR-VP16 transfected HepG2 cells at the same time point. The same amount of cDNA from calibrator, control and transfected cell extracts was mixed with 1XSYBR @ Green Taq ReadyMixe (Sigma), 50 ng sense and antisense primers (described above) and transfer into Lightcycler capillaries (Roche Diagnostics). The following conditions were used for the amplification of PCR products: denatured at 95 8C for 30 s; amplification at 58 8C for 5 s followed by 72 8C for 20 s for 50 cycles; cooldown at 40 8C for 2 min. The fluorescence signal was detected at the same time point of each cycle. Data were presented as the normalised ratio, which is the target/ reference ratio of the sample divided by the target/reference ratio of the calibrator by Lightcycler Relative Quantification software.
Secreted insulin measurement
Five day cultures of cells transfected with TTR-VP16 or TTR-XlHbox8VP16 were treated with either normal glucose (5.5 mM) or high glucose (25 mM) for 12 h. The media were concentrated by using Centricon YM-3 Centrifugal Filter Devices (Millipore Corporation, nominal molecular weight limit 3 KiloDalton). 15-20 ml medium were applied into the sample reservoir and centrifuged at 6500!g until all the medium had been filtrated; then the concentrated samples were collected into retentate vials by inverting the unit and centrifuging at 1000!g for 5 min. The total protein concentration was determined using the Bio-Rad Protein Assay (Bio-Rad Laboratories Ltd). The insulin concentration was analysed using a rat Insulin ELISA kit (Mercodia AB, Sweden) following the manufacturer's procedure. The samples and standards, which were different concentration of recombinant human insulin solution (Sigma, UK), were performed in triplicate for each set of assays.
4.11. Imaging processing by fluorescence or confocal microscopy Fluorescent specimens were examined under a Zeiss LSM 510 confocal microscope; images were collected and processed with Photoshop. For cell counting experiments, numbers of random fields were selected using the 20! or 40! objective lens of a Leica DMRB microscope and photographed with a digital spot camera (Image Solutions). The cell numbers was visualised by DAPI staining.
Statistical analysis
For the cell counting and replicate insulin secretion measurements the data were expressed as meanGSD. Comparison of individual treatment was conducted using Student's t-test.
